Mobile Stroke Units: A Game-Changing Innovation in Stroke Care
The most remarkable finding from the BEST-MSU trial (DOI: 10.1001/jamaneurol.2021.5321) is that mobile stroke units achieved a 65% increase in the odds of excellent functional outcomes at 90 days compared to conventional emergency medical services, while reducing treatment times by approximately 30 minutes 1, 2.
Key Clinical Findings
Functional Outcomes
The BEST-MSU trial demonstrated that patients eligible for thrombolysis who received MSU care had significantly better disability outcomes, with 55.0% achieving a modified Rankin Scale score of 0-1 (essentially no disability) at 90 days compared to only 44.4% with conventional EMS transport 1. This represents a clinically meaningful difference in real-world functional independence.
The "Golden Hour" Advantage
Perhaps the most striking operational finding: 97.1% of MSU patients received tissue plasminogen activator (tPA) compared to only 79.5% with standard EMS 1. The median time from stroke onset to tPA administration was slashed from 108 minutes with conventional care to just 72 minutes with MSU care 1. This 36-minute reduction is critical because every 15-minute delay in thrombolysis worsens outcomes.
Ultra-Early Treatment Rates
MSUs enabled treatment within the critical "golden hour" (60 minutes from symptom onset) at dramatically higher rates—with a 7.71-fold increase in odds of achieving this benchmark 2. The 2026 AHA/ASA guidelines specifically note that improved outcomes with MSUs were "strongly related to higher thrombolytic rates within the first golden hour" 3.
Safety Profile
Importantly, no safety concerns emerged: all-cause mortality, rates of symptomatic intracerebral hemorrhage, and treatment of stroke mimics were comparable between MSU and conventional care 3, 1, 2. At 90 days, mortality was actually lower in the MSU group (8.9% vs 11.9%) 1.
How MSUs Work
These specialized ambulances are equipped with:
- CT scanners for immediate brain imaging
- Point-of-care laboratory testing
- Neurological expertise (either on-board physicians or via telemedicine)
- Capability to administer tPA in the field 3
The interdisciplinary team brings emergency stroke care directly to the patient's location, eliminating the traditional delays of transport-then-diagnose-then-treat 3.
Clinical Impact Across the Disability Spectrum
Beyond the binary excellent/poor outcome measures, MSUs reduced disability across the full range of the modified Rankin Scale (adjusted common odds ratio 1.39), meaning benefits extended to patients at all levels of stroke severity 2. This suggests the intervention improves outcomes broadly, not just for a select subgroup.
Current Guideline Recommendations
The 2026 AHA/ASA guidelines now give MSUs a Class 1, Level A recommendation—the highest grade possible—for transport and management of thrombolytic-eligible patients where MSUs are available 3. This strong recommendation is based on multiple randomized trials and meta-analyses consistently demonstrating improved functional outcomes at 90 days 3.
Important Caveats
While MSUs excel for thrombolysis delivery, they have not yet demonstrated improved clinical outcomes for endovascular thrombectomy patients, though they may help with faster identification and triage to thrombectomy-capable centers 3. The guidelines note that obtaining CT angiography on board the MSU may improve door-to-puncture times for thrombectomy 3.
The Broader Significance
This represents a fundamental shift in stroke care delivery—bringing the hospital to the patient rather than the patient to the hospital. The 18% absolute improvement in outcomes across all disability strata cannot be explained solely by the increased golden-hour treatment rates, suggesting that immediate access to stroke expertise and imaging for all suspected stroke patients, regardless of symptom severity or duration, fundamentally improves care 4.